Navigation Links
New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
Date:10/17/2008

r meals only if blood glucose levels are elevated. Weight loss with liraglutide is attributed to the fact that it slows gastric emptying and leads to increased satiety after meals. Liraglutide is naturally broken down in the body and does not require renal excretion.

On May 23, 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration in the United States, as well as a marketing authorization application to the European Medicines Agency in Europe, for the approval of liraglutide for the treatment of people with type 2 diabetes. A New Drug Application was also submitted for approval in Japan on July 14, 2008.

About LEAD(TM) (Liraglutide Effect and Action in Diabetes)

LEAD(TM) (Liraglutide Effect and Action in Diabetes) 6 is the first trial to be reported from the phase 3b LEAD(TM) program. Topline results from the LEAD(TM) 6 study were released by Novo Nordisk in a Stock Exchange Announcement on June 6, 2008.

The phase 3a LEAD(TM) program, which comprised the regulatory filing documentation for liraglutide, included trials 1-5. The purpose of the LEAD(TM) program is to compare liraglutide directly against commonly used therapies in type 2 diabetes, except for metformin, with which it is used in combination.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visi
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... MA -- Trillions of bacteria live in each person,s ... help digest food and stave off harmful infections, but ... , To help shed light on the role of ... associate professor Eric Alm recently tracked fluctuations in the ... year. The findings, described in the July 25 issue ...
(Date:7/25/2014)... 25, 2014 WABC Radio show out of ... with Lorry Young will be hosting California-based Vet-Stem, Inc.’s Founder ... cell therapy in pets. Dr. Harman first visited the ... cell therapy for pets suffering from osteoarthritis and other degenerative ... Medicine industry forward. , Young has invited Dr. Harman back ...
(Date:7/25/2014)... BENSALEM, Pa. , July 25, 2014 /PRNewswire-iReach/ ... services and consulting for global corporations operating in ... will host its first annual Global User Group ... in historic Philadelphia, Pennsylvania ... Photo - http://photos.prnewswire.com/prnh/20140724/130263 ...
(Date:7/24/2014)... 24, 2014 -- A novel combination of microscopy and ... Energy,s Oak Ridge National Laboratory an unprecedented look at ... physical and electrochemical properties. , The research team ... the surface of a perovskite manganite, a complex material ... avenue to understand surface behavior could benefit researchers who ...
Breaking Biology Technology:Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3ORNL study reveals new characteristics of complex oxide surfaces 2
... Jeff Olson, Manager of Nucleic Acid Applications, of ... Loci for Targeted Sequencing Applications , ... on the new RDT 1000 instrument, at the 2009 ... Friday, February 6th, in Marco Island, Florida.RainDance Technologies is ...
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERES ... alliance to provide integrated Cardiac Safety and ... services to clinical trial sponsors and managers ... electrocardiographic (ECG), eClinical technology, ePRO, and other ...
... Roche announced today that it intends to commence a ... at US$ 86.50 per share. Roche, which currently owns 55.8% ... offer within approximately two weeks. The offer replaces the public ... all of the publicly-held shares of Genentech at a price ...
Cached Biology Technology:'Enrichment of Genomic Loci for Targeted Sequencing Application' Is Focus of 2009 AGBT Conference Workshop 2'Enrichment of Genomic Loci for Targeted Sequencing Application' Is Focus of 2009 AGBT Conference Workshop 3ERT (eResearchTechnology, Inc.) and Integrium, LLC Form Alliance to Deliver Integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring Services 2ERT (eResearchTechnology, Inc.) and Integrium, LLC Form Alliance to Deliver Integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring Services 3ERT (eResearchTechnology, Inc.) and Integrium, LLC Form Alliance to Deliver Integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring Services 4Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash 2Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash 3Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash 4Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash 5
(Date:7/25/2014)... of people lived on the land now called California, ... the availability of plants they used for food, fuel, ... to maintain desired habitat and natural resources. , Frank ... Southwest Station, will lead a field trip ... Ecological Society of America,s 99th Annual Meeting, in Sacramento, ...
(Date:7/25/2014)... wildfires have been raging this summer and some of the ... In this image collected by the Moderate Resolution Imaging ... a swath of smoke has descended over the Great Lakes ... is the fire image from July 23, 2014 (first image ... as it drifts off southeastward. In the image, it ...
(Date:7/25/2014)... online in the International Journal of Cancer ... cervical cancer based on findings showing successful reduction in ... discrete population of cells in the cervix. , ... squamocolumnar junction cells, or SCJ cells. These cells reside ... the origins of cervical cancer. A research team co-led ...
Breaking Biology News(10 mins):Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3Clearing cells to prevent cervical cancer 2
... Plastic additives known as phthalates (pronounced THAL-ates) are ... up in flooring, plastic cups, beach balls, plastic ... Disease Control and Preventionthe bodies of most Americans. ... increasing scrutiny. A growing collection of evidence suggests ...
... whale entangled in fishing gear, scientists showed for the ... and swimming behavior. The monitoring revealed how fishing gear ... energy as they drag gear for months or years, ... scientists in this entanglement response suction-cupped a cellphone-size device ...
... analysis shows that the nation,s land and water resources could ... to 25 billion gallons of algae-based fuel a year in ... The findings come from an in-depth look at the water ... algae in large, specially built shallow ponds. The results were ...
Cached Biology News:Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4
cysteine and glycine-rich protein 2,...
... pan B (B220), 4.5 m, coated ... efficient positive isolation or depletion of ... or lymph node cell suspensions. B220 ... cells and lytically active subsets of ...
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
NAP-2 (5C7)...
Biology Products: